全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
PLOS ONE  2013 

Boolean Network Model for Cancer Pathways: Predicting Carcinogenesis and Targeted Therapy Outcomes

DOI: 10.1371/journal.pone.0069008

Full-Text   Cite this paper   Add to My Lib

Abstract:

A Boolean dynamical system integrating the main signaling pathways involved in cancer is constructed based on the currently known protein-protein interaction network. This system exhibits stationary protein activation patterns – attractors – dependent on the cell's microenvironment. These dynamical attractors were determined through simulations and their stabilities against mutations were tested. In a higher hierarchical level, it was possible to group the network attractors into distinct cell phenotypes and determine driver mutations that promote phenotypic transitions. We find that driver nodes are not necessarily central in the network topology, but at least they are direct regulators of central components towards which converge or through which crosstalk distinct cancer signaling pathways. The predicted drivers are in agreement with those pointed out by diverse census of cancer genes recently performed for several human cancers. Furthermore, our results demonstrate that cell phenotypes can evolve towards full malignancy through distinct sequences of accumulated mutations. In particular, the network model supports routes of carcinogenesis known for some tumor types. Finally, the Boolean network model is employed to evaluate the outcome of molecularly targeted cancer therapies. The major find is that monotherapies were additive in their effects and that the association of targeted drugs is necessary for cancer eradication.

References

[1]  Weinberg R (2007) The biology of cancer. New York: Garland Science.
[2]  Kumar V, Abbas AK, Aster JC, Fausto N (2010) Robbins and Cotran pathologic basis of disease. 8th ed. Philadelphia: W.B. Saunders Co.
[3]  Siegel R, Ward E, Brawley O, Jermal A (2011) Cancer Statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61: 212–236.
[4]  Murray CJL, Lopez AD (1997) Alternative projections of mortality and disability by cause, 1920–2020: Global burden of disease study. Lancet 349: 1448–1504.
[5]  Clark WH (1991) Tumour progression and the nature of cancer. Br. J. Cancer 64: 631–644.
[6]  Martins ML, Ferreira Jr SC, Vilela MJ (2009) Multiscale model for biological systems. Curr. Opin. Colloid Interface Sci. 15: 18–23 (2010)..
[7]  Kauffman SA (1993) The origins of order: Self-organization and selection in evolution. New York: Oxford University Press.
[8]  Davidich MI, Bornholdt S (2008) Boolean network model predicts cell cycle sequence of fission yeast. PLoS One 3(2): e1672.
[9]  Fauré A, Naldi A, Chaouiya C, Thieffry D (2006) Dynamical analysis of a generic Boolean model for the control of the mammalian cell cycle. Bioinformatics 22(14): e124.
[10]  Silva HS, Martins ML (2003) A cellular automata model for cell differentiation. Phys. A 322: 555–566.
[11]  Saez-Rodrigues J, Simeoni L, Lindquist JA, Hemenway R, Bommhardt U, et al. (2007) A logical model provides insights into T cell receptor signaling. PLoS Comput. Biol. 3(8): e163.
[12]  Schlatter R, Schmich K, Vizcarra IA, Scheurich P, Sauter T, et al. (2009) ON/OFF and beyond - A Boolean model of apoptosis. PLoS Comput. Biol. 5(12): e1000595.
[13]  Mai Zhongxing, Liu Haiyan (2009) Boolean network-based analysis of the apoptosis network: irreversible apoptosis and stable surviving. J. Theor. Biol. 259: 760–769.
[14]  Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70.
[15]  Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646–674.
[16]  Vogelstein B, Kinzel KW (2004) Cancer genes and the pathways they control. Nat. Med. 10(8): 789–799.
[17]  Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 1: 8–24.
[18]  Calzone L, Gelay A, Zinovyev A, Radvanyi F, Barillot E (2008) A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol. Syst. Biol 4: 173.
[19]  Newman MEJ (2010) Networks: An Introduction. New York: Oxford University Press.
[20]  Evan GI, Vousden KH (2001) Proliferation, cell cycle, and apoptosis in cancer. Nature 411: 342–348.
[21]  Lendahl U, Lee KL, Yang H, Poellinger L (2009) Generating specificity and diversity in the transcriptional response to hypoxia. Nat. Rev. Genet. 10: 821–832.
[22]  Bunz F (2008) Principles of cancer genetics. Berlin: Springer.
[23]  Luo J, Solimini NL, Elledge S (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823–837.
[24]  Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS (2010) A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 10: 59–64.
[25]  Stratton MR, Campbell DJ, Futreal PA (2009) The cancer genome. Nature 458: 719–724.
[26]  Stephens PJ, Tarpey PS, Davies H, Loo PV, Greenman C, et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400–404.
[27]  Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405–409.
[28]  Sj?blom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
[29]  The Cancer Genome Atlas Research Network (2011) Integrated genomic analysis of ovarian carcinoma. Nature 474: 609–615.
[30]  Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, et al. (2010) A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184–190.
[31]  The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068.
[32]  The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519–525.
[33]  The Cancer Genome Atlas Research Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 467: 330–337.
[34]  Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481: 306–313.
[35]  Ferreira Jr SC, Martins ML, Vilela MJ (2002) Reaction-diffusion model for the growth of avascular tumor. Phys.Rev.E 65: 021907.
[36]  Paiva LR, Binny C, Ferreira Jr SC, Martins ML (2009) A multiscale mathematical model for oncolytic virotherapy. Cancer Res. 69: 1205–1211.
[37]  KEGG Pathway database, Kyoto Encyclopedia of Genes and Genomes. Available at http://www.genome.jp/kegg/pathway.html.
[38]  Vanhaesebroeck B, Stephens L, Hawkins P (2012) PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13(3): 195–203.
[39]  Keith B, Johnson RS, Celeste Simon M (2012) HIF1 and HIF2: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12(1): 9–22.
[40]  Yarden Y, Pines G (2012) The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12(8): 553–563.
[41]  Massague J (2012) TGF signalling in context. Nature Rev. Mol. Cell Biol. 13: 616–630.
[42]  Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13: 11–26.
[43]  Cotter TG (2009) Apoptosis and cancer: the genesis of a research field. Nat. Rev. Cancer 9: 501–507.
[44]  Batchelor E, Loewer A, Lahav G (2009) The ups and downs of p53: understanding protein dynamics in single cells. Nat. Rev. Cancer 9: 371–377.
[45]  Balkwill F (2009) Tumour necrosis factor and cancer. Nat. Rev. Cancer 9: 361–371.
[46]  Karin M, Cao Y, Greten FR, Li ZW (2002) NF-B in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2: 301–310.
[47]  Smoot M, Ono K, Ruscheinski J, Wang PL, Ideker T (2010) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27(3): 431–432. Cytoscape is available for download at http://www.cytoscape.com.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133